These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38400671)

  • 21. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
    Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
    Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
    Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
    Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
    Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender J; Blaney SM; Borinstein S; Reid JM; Baruchel S; Ahern C; Ingle AM; Yamashiro DJ; Chen A; Weigel B; Adamson PC; Park JR
    Clin Cancer Res; 2012 Sep; 18(18):5081-9. PubMed ID: 22791883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
    Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
    Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
    Shimizu T; Kuboki Y; Lin CC; Yonemori K; Yanai T; Faller DV; Dobler L; Gupta N; Sedarati F; Kim KP
    Target Oncol; 2022 Jan; 17(1):15-24. PubMed ID: 34843044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
    Baginska J; Nau A; Gomez Diaz I; Giobbie-Hurder A; Weirather J; Vergara J; Abrecht C; Hallisey M; Dennis J; Severgnini M; Huezo J; Marciello I; Rahma O; Manos M; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Ott PA; Buchbinder EI; Hodi FS
    Cancer Immunol Immunother; 2024 Jan; 73(1):17. PubMed ID: 38236249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
    Diaz-Padilla I; Siu LL; San Pedro-Salcedo M; Razak AR; Colevas AD; Shepherd FA; Leighl NB; Neal JW; Thibault A; Liu L; Lisano J; Gao B; Lawson EB; Wakelee HA
    Br J Cancer; 2012 Aug; 107(4):604-11. PubMed ID: 22805331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
    Choueiri TK; Porta C; Suárez C; Hainsworth J; Voog E; Duran I; Reeves J; Czaykowski P; Castellano D; Chen J; Sedarati F; Powles T
    Oncologist; 2022 Dec; 27(12):1048-1057. PubMed ID: 36146944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.
    Camera S; Deleporte A; Bregni G; Trevisi E; Pretta A; Telli TA; Polastro L; Gombos A; Kayumba A; Ameye L; Piccart-Gebhart M; Awada A; Sclafani F; Hendlisz A
    Clin Colorectal Cancer; 2020 Dec; 19(4):311-318.e1. PubMed ID: 32631787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
    Freyer G; Isambert N; You B; Zanetta S; Falandry C; Favier L; Trillet-Lenoir V; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Fumoleau P
    Br J Cancer; 2012 Aug; 107(4):598-603. PubMed ID: 22790797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Riechelmann RP; Srimuninnimit V; Bordonaro R; Kavan P; Di Bartolomeo M; Maiello E; Cicin I; García-Alfonso P; Chau I; Fedyanin MY; Martos CF; Ter-Ovanesov M; Peeters M; Ko YJ; Yalcin S; Karthaus M; Aparicio J; Heinemann V; Picard P; Bury D; Drea E; Sobrero A
    Clin Colorectal Cancer; 2019 Sep; 18(3):183-191.e3. PubMed ID: 31221542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
    Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
    Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
    Lim B; Potter DA; Salkeni MA; Silverman P; Haddad TC; Forget F; Awada A; Canon JL; Danso M; Lortholary A; Bourgeois H; Tan-Chiu E; Vincent S; Bahamon B; Galinsky KJ; Patel C; Neuwirth R; Leonard EJ; Diamond JR
    Clin Cancer Res; 2021 Jun; 27(12):3329-3338. PubMed ID: 33820779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
    Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
    Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.